INVO Fertility (NASDAQ:IVF – Get Free Report) posted its earnings results on Tuesday. The company reported $472.78 earnings per share for the quarter, FiscalAI reports. The company had revenue of $1.60 million for the quarter.
INVO Fertility Stock Up 3.4%
Shares of NASDAQ:IVF opened at $1.52 on Wednesday. The firm has a fifty day simple moving average of $2.09 and a two-hundred day simple moving average of $5.20. INVO Fertility has a 52 week low of $1.38 and a 52 week high of $198.00. The stock has a market capitalization of $2.46 million, a P/E ratio of 0.00 and a beta of 2.33.
Analyst Upgrades and Downgrades
IVF has been the subject of a number of research analyst reports. Wall Street Zen upgraded INVO Fertility from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings raised INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Finally, Maxim Group set a $20.00 price objective on INVO Fertility in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.00.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC acquired a new position in shares of INVO Fertility, Inc (NASDAQ:IVF – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility at the end of the most recent reporting period. 12.02% of the stock is currently owned by institutional investors and hedge funds.
About INVO Fertility
INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.
The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.
Read More
- Five stocks we like better than INVO Fertility
- Tomato Prices Are Spiking, and These 2 Food Stocks Could Feel the Squeeze
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
Receive News & Ratings for INVO Fertility Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Fertility and related companies with MarketBeat.com's FREE daily email newsletter.
